Clinical trials: Lymphatic System Neoplasm
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Hematological Malignancies
Rituximab for Prevention of Chronic GVHD
The purpose of this trial is to determine if administration of rituximab after allogeneic stem cell transplantation can reduce the incidence of chronic GVHD.
- Trial name
- NCT00379587
- Testing
- Rituximab, 375 mg/m2 RRituximab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT04191187
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA).
- Trial name
- NCT02064387
- Testing
- GSK2857916
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Multiple Myeloma
Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Current therapies for Multiple Myeloma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Multiple Myeloma.
- Trial name
- NCT00003511
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Burzynski Research Institute
Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT01659021
- Testing
- Idelalisib, Ofatumumab
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 261 people
- Sponsor
- Gilead Sciences
Refractory Multiple Myeloma
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating patients with multiple myeloma (MM) previously treated with lenalidomide.
- Trial name
- NCT01301963
- Testing
- plerixafor, filgrastim
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm
Exercise Prehab in Older Adults With Hematologic Malignancies
This pilot trial studies a structured exercise program intervention in improving physical activity in older patients with hematologic malignancies undergoing cancer therapy.
- Trial name
- NCT02791737
- Testing
- Exercise Intervention, Laboratory Biomarker Analysis, Physical Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hematologic Malignancies, Graft vs Host Disease
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
The proposed research study is to test the drug vorinostat, in a new use as an additional medication, with other standard treatments for the prevention of severe acute graft versus host disease (GVHD).
- Trial name
- NCT00810602
- Testing
- reduced intensity, related donor stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis)
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Pavan Reddy, MD
Plasma Cell Myeloma
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
This phase II trial studies how well daratumumab works in treating transplant-eligible patients with multiple myeloma. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
- Trial name
- NCT03477539
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Lenalidomide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well panobinostat, carfilzomib, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT03256045
- Testing
- Carfilzomib, Chemosensitivity Assay, Dexamethasone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Washington
Non-Hodgkin's Lymphoma
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
This open-label, multicenter, randomized Phase III study will investigate the efficacy, safety, pharmacokinetics and pharmacoeconomics of obinutuzumab (RO5072759, GA101) combined with bendamustine followed by continued…
- Trial name
- NCT01059630
- Testing
- Obinutuzumab, Bendamustine
- Where
- 121 sites in United States, Austria and 12 more
- Volunteers
- 413 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Japanese participants with…
- Trial name
- DREAMM 7 (NCT06868667)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 16 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
This was an open-label, single-arm, pilot study of the recombinant MAGE-A3 protein plus the immunological adjuvant AS15 (recMAGE-A3 + AS15) in subjects with symptomatic multiple myeloma who had completed induction therapy with at…
- Trial name
- NCT01380145
- Testing
- recMAGE-A3 Protein + AS15 Adjuvant
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Ludwig Institute for Cancer Research
Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute…
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma
- Trial name
- NCT01190930
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- 243 sites in United States, Australia and 5 more
- Volunteers
- 9,350 people
- Sponsor
- Children's Oncology Group
Lymphoma
Phase II Study of TAK228 in Relapsed Lymphoma
The goal of this clinical research study is to learn if TAK-228 can help to control relapsed lymphoma. The safety of this drug will also be studied.
- Trial name
- NCT02727777
- Testing
- TAK228, Blood Sugar Testing
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Leukemia
Alemtuzumab and Pentostatin In T-cell Neoplasms
The goal of this clinical research study is to learn if giving pentostatin with alemtuzumab can help to control T-cell malignancy. The safety of this combination therapy will also be studied.
- Trial name
- NCT00453193
- Testing
- Pentostatin, Alemtuzumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma
The purpose of this study is to determine efficacy of treatment with bortezomib (in combination with doxorubicin and dexamethasone) in previously untreated patients with Multiple Myeloma.
- Trial name
- NCT00872521
- Testing
- PAD induction
- Where
- 16 sites in Australia
- Volunteers
- 107 people
- Sponsor
- Janssen-Cilag Pty Ltd
Follicular Lymphoma, Small Lymphocytic Lymphoma
Imexon for Relapsed Follicular and Aggressive Lymphomas
The purpose of this study is to determine whether Amplimexon (imexon for injection) is effective in the treatment of indolent and aggressive lymphomas that have progressed after treatment with standard therapies.
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma
- Trial name
- ULYM11011 (NCT01314014)
- Testing
- Imexon
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Rochester
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.